BackKrystal Biotech Overview
Krystal Biotech Inc

Krystal Biotech Target Price

See Krystal Biotech's analyst price targets ($380) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$371.47

Average Target Price

$383.753.3% upside

4 analysts in the last 4 months

High: $474 | Low: $300

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-14RBC CapitalLisa Walter$4007.7% upsideOpen
2026-07-13Jefferies$47427.6% upsideOpen
2026-06-16H.C. WainwrightJoseph Pantginis$3612.8% downsideOpen
2026-05-05Evercore ISI$30019.2% downsideOpen
2026-02-18Chardan CapitalGeulah Livshits$32313% downsideOpen
2026-02-17JefferiesRoger Song$3710.1% downsideOpen
2026-01-30Goldman Sachs$32712% downsideOpen
2026-01-09H.C. Wainwright$31016.5% downsideOpen
2025-10-17GuggenheimDebjit Chattopadhyay$22439.7% downsideOpen
2025-08-22Chardan Capital$21641.9% downsideOpen
2024-09-11Stifel NicolausDae Gon Ha$22040.8% downsideOpen
2024-09-02Bank of America SecuritiesAlec Stranahan$20544.8% downsideOpen
2024-08-12Evercore ISIGavin Clark-Gartner$20644.5% downsideOpen
2024-04-15Stifel NicolausDae Gon Ha$20445.1% downsideOpen
2022-11-07Chardan CapitalGeulah Livshits$13364.2% downsideOpen
2022-08-08Chardan CapitalGeulah Livshits$13065% downsideOpen

Krystal Biotech (KRYS) FAQ

Krystal Biotech's target price stands at $380. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $380 for KRYS implies 3.3% upside versus today's price ($371.47). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Krystal Biotech's target price evolved across reporting periods, while the comparison chart places KRYS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Krystal Biotech's reading of $380 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.